Ankura Hospitals has secured Rs 165 crore in funding from the Asian Development Bank. This strategic investment will enhance its pediatric, maternity, and gynecology services, enabling the Hyderabad-based chain to expand its facilities and strengthen its presence in key cities across India.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hmIAXlY
via...
KKR in talks to acquire US dental labs chain Leixir
Global investment firm KKR is in talks to acquire Leixir Dental Laboratory Group from Comvest Investment Partners at a valuation of $200-$250 million. Leixir, founded in 2013, offers various dental solutions and operates facilities in the US and India. Deloitte is advising on the sale process.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aeon5HM
via...
From AI to Telemedicine: Digital skills every healthcare professional should learn
Digital skills are crucial for healthcare professionals, with growing fields like telemedicine, AI-driven diagnostics, and data analytics. Continuous learning in electronic health records, cybersecurity, and emerging technologies like 3D printing and robotics is vital for those seeking to stay relevant and succeed in the evolving healthcare landscape.
from...
Eli Lilly working on a heart drug that may benefit Indians: CEO David Ricks
Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, potentially reducing it by 85%-90%. With heart disease cases surging in India, this phase 3 trial drug promises significant cardiovascular benefits, requiring only once-a-year administration. It's crucial, given the rising heart...
47 drugs found 'not of standard quality' in February
The Central Drugs Laboratories identified 47 drug samples as 'not of standard quality' in February, while State Drugs Testing Laboratories found 56 similar samples. One drug from West Bengal was found spurious and made by an unauthorized manufacturer. Regular action is taken to remove such drugs from the market.
from Healthcare/Biotech-Industry-Economic...
Essential medicines will cost you a bit more from April 1
Beginning April 1, prices for essential drugs like painkillers, antibiotics, and anti-diabetic medicines will rise by 1.74%. The increase is based on the change in the wholesale price index. The pharmaceutical industry is pushing for higher price hikes to counterbalance increased input costs over recent years.
from Healthcare/Biotech-Industry-Economic...
Kedaara, TA Associates vie for minority stake in Sagent Pharma
Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 million. Investment amounts are estimated between $150-200 million. Originally acquired by Ravi Penmetsa's Ellimist Singapore, Sagent specializes in generic injectables for the US market.
from Healthcare/Biotech-Industry-Economic...
Donor aid cuts may undo years of progress in combating HIV: Study
US President Trump's decision to suspend USAID programmes and fund cuts by other countries could lead to 10.8 million new HIV infections and 2.9 million HIV-related deaths by 2030 in low-and-middle-income countries. Major donor funding cuts may reverse decades of progress against HIV/AIDS, especially in sub-Saharan Africa and among vulnerable populations.
from...
Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute
The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kI9mxiE
via...
Open to tie-ups in India for selling Mounjaro: Eli Lilly CEO David Ricks
Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched in India. Priced significantly lower than in the US, Mounjaro's introduction anticipates strong demand in the country with over 100 million obese and diabetic individuals.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly's goal is to reach everyone who needs obesity care: Global CEO David Ricks
Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and emphasizes the importance of partnerships, including with Indian tech companies and governments, for tackling chronic diseases and improving public health...
India develops its first indigenous MRI machine, to reduce treatment costs
India has developed its first indigenous MRI machine to be installed at AIIMS Delhi by October for trials, reducing dependency on imports by 80-85%. An MoU was signed with SAMEER for the installation. The Ministry of Electronics and Information Technology is spearheading this technological advancement aimed at achieving self-reliance in medical technology.
from...
Meghalaya’s Gnanamma Healthcare Centre transitions to near net-zero electricity health facility
Gnanamma Healthcare Centre in Guwahati celebrates its transition to a near net-zero electricity facility with a new 6.05kW solar plant and battery energy storage. This upgrade ensures reliable power, especially for critical services like vaccine storage and emergency care, reducing carbon emissions and setting an example for sustainable healthcare...
Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing public interest and high prices. Natco is required to maintain detailed financial records and may owe damages if Roche ultimately wins the case.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zsjncES
via...
Heartening news: Device made in India to help transplant patients
India plans to develop cost-effective left ventricular assist devices (LVADs) to aid end-stage heart failure patients while they wait for donor hearts. With an estimated 50,000 patients needing heart transplants annually but a severe shortage of donor hearts, indigenously made LVADs could reduce costs and increase foreign medical visitors. Development...
₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis
India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce weight-loss drugs in the market. The economic impact is enormous, and local generics are preparing to offer more affordable alternatives to combat this growing health issue.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1XhQp5n
via...
Bharat Biotech invests Rs 600 cr to expand into cell, gene therapies
As per Bharat Biotech, the facility will tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival. Work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia.
from Healthcare/Biotech-Industry-Economic...
Entero Healthcare launches HealthEdge programme for chemists
Entero Healthcare Solutions launched the 'HealthEdge' program to modernise retail pharmacies and improve efficiency for over 86,000 chemists. The company also acquired the Aayu Chemist app and Medcords platform, aimed at enhancing profits and customer engagement. Entero reported significant revenue and profit growth in FY 2025 Q3.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising obesity and diabetes rates, India presents a significant market opportunity for the U.S.-based company. Mounjaro is already marketed in the UK and Europe for both conditions and under the name Zepbound for obesity in the U.S.
from...
India has a chance to lead in health space amid Global North's funding cuts: Gates Foundation CEO Mark Suzman
Mark Suzman, CEO of the Gates Foundation, sees the current global funding challenges as an opportunity for India to lead, particularly in health and development. Amid funding cuts from the US, UK, and France, Suzman remains optimistic about mobilizing resources for life-saving initiatives, highlighting India's cost-effective innovations.
from Healthcare/Biotech-Industry-Economic...
Impose safeguard duties on medical devices: AiMeD
The Association of Indian Medical Device Industry (AiMeD) has requested the government to impose safeguard duties on 12 medical device categories to shield domestic manufacturers from cheap imports. AiMeD highlighted a significant increase in imports, notably in syringes and needles, primarily from China, the US, and Singapore.
from Healthcare/Biotech-Industry-Economic...
AI, teleconsultation, modern tech being used in treatment, diagnosis: Nadda
Health Minister JP Nadda emphasized the government's commitment to enhancing healthcare through policies incorporating AI for TB detection, modern cancer treatments, and mental health teleconsultation. The goal is to increase health expenditure to 2.5% of GDP, currently at 1.84%, showcasing substantial achievements in improving maternal and child mortality...
Health expenditure now at 1.84 pc of GDP, moving steadily to 2.5 pc: JP Nadda
Union Health Minister JP Nadda stated that the Indian government’s health expenditure has reached 1.84% of GDP, moving towards the 2.5% target by 2025. From 2013-14's Rs 38,000 crore, current health allocations are nearly Rs 1 lakh crore. The National Health Policy 2017 aims to increase healthcare funding, with 1.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug
Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate cancer treatment. These tablets will be produced at their Ahmedabad facility. Apalutamide, an androgen receptor inhibitor, is intended for metastatic castration-sensitive prostate cancer and had annual sales of USD 1,099.8 million...
India weighs lower tariffs for US medical devices amid trade talks
The Indian government is considering lowering tariffs on US medical devices to mitigate potential US tariff threats on Indian exports. While this aims to ease trade tensions, industry experts express concerns about the impact on India's self-reliance. Stakeholders suggest reciprocal market access as Indian exporters face high regulatory barriers in...
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials
Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom 'B-cell' tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies.
from...
AIIMS critically short of staff amid land & budgetary issues
AIIMS in New Delhi is experiencing severe staff shortages, with hundreds of vacant posts for doctors and faculty members. A parliamentary committee has urged the health ministry to offer competitive compensation and prioritize the filling of these positions. Additionally, the slow progress of AIIMS' expansion projects has been criticized.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma, Zydus recall products in US: USFDA report
Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the USFDA. Sun Pharma is recalling Morphine Sulfate tablets for failed dissolution specifications, while Zydus is recalling Nelarabine Injection for failed impurities/degradation specifications.
from Healthcare/Biotech-Industry-Economic...
Skin cream, nasal spray, and... blindness? AIIMS doctors warn steroids misuse could trigger silent vision loss
Frequent use of steroid-based treatments for respiratory issues, allergies, and skin conditions can heighten the risk of glaucoma. Experts at AIIMS stress the importance of regular eye check-ups for early detection. Lifelong care and awareness programs at the primary care level are essential for preserving vision.
from Healthcare/Biotech-Industry-Economic...
Struggling with dry eyes? Haldi's power-packed compound might be the relief you need
A study by AIIMS reveals that bio-enhanced curcumin, found in turmeric (haldi), effectively treats mild to moderate dry eye disease by improving tear stability and reducing inflammation. The clinical trial showed significant improvements in tear metrics and symptoms, suggesting a natural, side-effect-free alternative treatment.
from Healthcare/Biotech-Industry-Economic...
China’s biotech is redrawing the global pharma map; what India can learn
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. AstraZeneca signed a deal with CSPC Pharma for a cardiac treatment, while Merck signed a $2 billion deal with Hansoh Pharma. Indian drugmakers are also collaborating with Chinese rivals. Mankind Pharma partnered with...
Parliamentary panel flags brain drain from health dept, delay in filling vacancies in research posts
A parliamentary committee has raised concerns about unoccupied posts of scientists in the Department of Health Research and recommended stopping contractual appointments to prevent brain drain. The panel emphasized enhancing higher education and research infrastructure, improving standards of living, and offering competitive pay to retain Indian professionals.
from...
Parl panel on health: Cos scared to set up units due to CDSCO approach
The Parliamentary Standing Committee on Health and Family Welfare criticized the Central Drugs Standard Control Organisation (CDSCO) for delays and lack of transparency in the drug licensing process. They recommended streamlining the system and establishing an independent advisory board to improve India's medical device industry.
from Healthcare/Biotech-Industry-Economic...
Dr. Reddy’s recalls mislabelled Levetiracetam injection in the US; patients likely to experience 'adverse' events
Dr. Reddy’s Laboratories is recalling a batch of Levetiracetam injection bags in the U.S. due to incorrect labeling, which could result in patients receiving a double dose. The error poses serious health risks, including hypersensitivity, liver injury, and respiratory depression. The mislabeled batch was distributed nationwide between November 4 and...
Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared to domestic drugs. The findings have drawn criticism from the Indian Pharmaceutical Alliance, which disputes the study’s methodology and its implications on quality and efficacy.
from Healthcare/Biotech-Industry-Economic Times...
Global buyout funds line up for AGS Health
Global buyout funds are eyeing AGS Health, valuing the IT firm at around $1 billion. EQT Partners, the current owner, plans to launch the sale early next year. AGS Health, acquired by EQT in 2019 for $320 million, provides RCM services with 12,000 employees and significant revenue. Interest in healthcare BPOs is rising among private equity firms.
from...
New affordable diabetes drug Empagliflozin launched in India
Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheim’s patent. Mankind Pharma’s version is priced at Rs 5.50 per tablet, a reduction of 90%. This move is expected to improve access to affordable diabetes treatment in India.
from...
Zydus eyes major stake in French medtech Amplitude for Rs 2,446 crore
India's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global medical devices market. The acquisition, at a premium of nearly 81% to Amplitude's last close, aims to leverage growth opportunities in surgical technologies for lower-limb orthopedics and expand internationally.
from...
India, vaccine superpower; manufactures 60% of global supply: ICMR former chief
India's Thiruvananthapuram has become a vaccine superpower, producing 60 per cent of the world's vaccines, with significant contributions from Pune. India's efficient vaccine development and distribution, spearheaded by government-supported research and a National Task Force, have positioned the country as a leader in global health. This effort notably...
Zydus Lifesciences to buy 86% stake in French medical devices maker
India's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global medical devices market. The acquisition, at a premium of nearly 81% to Amplitude's last close, aims to leverage growth opportunities in surgical technologies for lower-limb orthopedics and expand internationally.
from...
ET Q&A: All our products are legitimate, sold under valid prescriptions, says Aveo Pharmaceuticals MD
Aveo Pharmaceuticals asserts that a stop-production notice was issued due to non-compliance with GMP standards, not for exporting opioid-based drugs. They have taken corrective measures and are working with authorities, aiming to resume operations soon, as many livelihoods depend on it.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5FvT3o8
via...
India's Syngene International acquires first US biologics facility for $36.5 million
India's Syngene International has agreed to acquire its first biologics facility in the U.S. from Emergent Manufacturing for $36.5 million. This move aims to expand Syngene's capabilities in the Northeast U.S. and reduce dependence on China, with the facility expected to be operational by mid-2025.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IT3gfWs
via...
Zydus Lifesciences gets USFDA nod to market generic antifungal shampoo
Zydus Lifesciences received approval from the USFDA to market Ketoconazole Shampoo, an antifungal medication, in the US. This approval is for a generic version targeting dandruff and various fungal infections. The medication will be produced at Zydus's manufacturing site in Ahmedabad. As of January 2025, its annual US sales were valued at USD 68.89...
Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mn
Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, UNLOXCYT, to a broader market. The acquisition enhances Sun Pharma's oncology portfolio and aims to provide a new treatment option for cSCC patients. Completion is expected by the...
Keep tobacco and alcohol ads and their proxies off IPL, Health ministry tells cricket board
The health ministry has urged the IPL and cricket board to ban all tobacco and alcohol advertising at matches and related events, and on national TV broadcasts. The letter emphasizes the crucial role of sports in promoting public health, noting that tobacco and alcohol are major risk factors for non-communicable diseases, which account for over 70%...
USFDA pulls up Granules India for lapses in maintaining storage facilities, equipment at Telangana plant
The USFDA has issued a warning to Granules India for contamination and improper equipment maintenance at its Telangana facility. Inspectors found significant contamination, bird droppings, and torn CGMP records during their visit. The agency demands prompt corrective actions from the company to rectify these violations, emphasizing the need for effective...
Protecting your heart and managing diabetes: The power of a holistic lifestyle
Adopting a holistic lifestyle can significantly improve heart health and manage diabetes. Key strategies include a balanced diet, regular physical activity, stress management, maintaining healthy weight, and regular health check-ups. These habits are crucial for reducing the risk of heart disease and improving overall well-being.
from Healthcare/Biotech-Industry-Economic...
Indian Pharmaceutical Alliance calls for zero import duty on US drugs to boost local industry
The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero. Currently, India imposes a 10% tariff on US drugs, but the US does not charge any import duty on Indian drugs. This suggestion aims to support the Indian pharma industry by lowering costs.
from Healthcare/Biotech-Industry-Economic...
Registration for Ayushman Bharat to start after March 8: Delhi health minister
Delhi Health Minister Pankaj Singh announced that the registration for the Ayushman Bharat scheme in the national capital will begin after March 8. He assured that significant improvements in healthcare infrastructure and transparency in hospital operations would be implemented within 100 days, emphasising a focus on economically weaker sections and...
Apollo Health picks up controlling stake in Lucknow-based Care Diagnostics
Apollo Health & Lifestyle Limited has obtained a significant controlling stake in Care Diagnostics through an all-cash deal. This strategic partnership will position Care Diagnostics to expand its healthcare testing services more widely across Uttar Pradesh, with plans to achieve full acquisition eventually.
from Healthcare/Biotech-Industry-Economic...
AstraZeneca gets nod to import, sell hyperkalaemia treatment drug in India
AstraZeneca Pharma India Ltd has received approval from India's drug regulator to import and sell sodium zirconium cyclosilicate powder for treating hyperkalaemia in adults. This clearance enables the launch of Lokelma in India, contingent on obtaining related statutory approvals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dKLQ2F9
via...
Lasik surgery in 10 seconds? This AI-powered tech may challenge the traditional course of treatment for eye care
A city-based private eye hospital has introduced a breakthrough in LASIK surgery, achieving treatment time under 10 seconds per eye using AI technology. This innovation enhances accuracy and offers personalized treatment plans, consistently achieving a 99% to 100% success rate, designed to quickly and effectively correct vision for suitable patients.
from...
Clinical research entities asked to register by April 1
India's drug regulatory authority mandates all clinical research organisations to register through the SUGAM portal by April 1 to enhance transparency and accountability in the industry. This move aims to hasten clinical trials and create a comprehensive database of clinical research organisations, with India currently contributing just 3-4% to global...
Aurobindo unit terminates pact with Singapore firm to develop pentavalent vaccine
Aurobindo Pharma has terminated a license agreement through its subsidiary Auro Vaccines with Hilleman Laboratories for developing a pentavalent vaccine for children. The company asserted that this step would not materially affect its financial situation, as Auro Vaccines is not a crucial subsidiary. Despite this, Aurobindo Pharma shares rose 3.83%...
India set to introduce list of OTC drugs this month
India is set to receive a list of drugs transitioning to over-the-counter (OTC) status from prescription-only status soon. The committee responsible is finalizing the report to ensure public health is not at risk, with the report to be submitted to the Drugs Technical Authority Board shortly.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LCyYDsi
via...
Senores Pharma to acquire 14 ANDAs from Dr Reddy's Laboratories
Senores Pharmaceuticals of Gujarat has signed an agreement to acquire 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories. The acquisition, funded through IPO proceeds, includes 13 USFDA-approved ANDAs. This expands Senores' product offerings in the US and other regulated markets, addressing an opportunity worth USD 421 million.
from...
Zydus to develop combination vaccine for shigellosis and typhoid
Zydus Lifesciences is set to develop a combination vaccine against shigellosis and typhoid with the Gates Foundation's support. The vaccine aims to protect children under five in regions where both diseases are prevalent. Early-stage development and studies are scheduled to begin in March 2025. Collaboration with partners leverages Zydus' expertise...
Diabetes and obesity: The dangerous duo you need to break up with
World Obesity Day, observed on March 4th, emphasizes the dangers of the combined effects of diabetes and obesity, termed 'diabesity.' This harmful partnership increases the risk of severe health issues like heart disease, kidney damage, and nerve pain. The observance calls for lifestyle changes and medical interventions to manage and break free from...
AstraZeneca Pharma India gets CDSCO approval to import, sell cancer treatment medicine
AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab solutions. This approval allows the marketing of Durvalumab in combination with Tremelimumab for treating unresectable hepatocellular carcinoma in India, pending related statutory approvals.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma aims to launch anti-obesity and type 2 diabetes drug Utreglutide in five years: Dilip Shanghvi
Sun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutide in the next four to five years, said Managing Director Dilip Shanghvi. The drug is a GLP-1 receptor agonist and has shown promising results in early trials. Sun Pharma is focusing on launching the drug in India...
Glenmark acquires Acetylcysteine injection, launches in US market
Glenmark Pharmaceuticals Ltd acquired the generic version of Acetylcysteine injection from Aspen Pharma USA Inc and launched it in the US market. The injection is used to treat acetaminophen overdose and is expected to have the same therapeutic effect as the listed drug Acetadote Injection.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ghFB3pL
via...
Glenmark recalls 15 lakh bottles of ADHD medication in US: USFDA
Glenmark Pharmaceuticals is recalling around 14.76 lakh bottles of Atomoxetine Capsules due to detected CGMP deviations and the presence of N-Nitroso Atomoxetine impurity above FDA recommended limits. The recall is classified as Class II, indicating potential temporary or medically reversible adverse health consequences.
from Healthcare/Biotech-Industry-Economic...
Reciprocal tariffs may make Indian generic drugs costlier in US: Pharma giants on Trump stance
Indian pharmaceutical industry leaders indicate that proposed US tariffs on pharmaceutical exports may lead to increased drug costs and potential shortages in the US. They argue that the tariffs might be absorbed by consumers and stress the significant cost savings that affordable Indian generics provide to the US healthcare system.
from Healthcare/Biotech-Industry-Economic...
Our healthcare, education systems being plagued by commodification and commercialisation: Dhankhar
Vice President Jagdeep Dhankhar emphasized that healthcare and education should not be driven by commodification and commercialisation. Speaking at KPB Hinduja College in Mumbai, he highlighted the importance of Sanatan in India's culture for its inclusivity and its role in fostering equality through education.
from Healthcare/Biotech-Industry-Economic...
Aim to open 20,000 Jan Aushadhi centers by the end of 2025: Union Health Minister JP Nadda
Union Health Minister JP Nadda flagged off the Jan Aushadhi Raths for the Jan Aushadhi Saptah from March 1 to 7, aiming to open 20,000 Jan Aushadhi centres by the end of 2025. Events during the week will raise awareness about affordable generic medicines. Sanitary pads will also be offered at Rs 1 to promote menstrual hygiene.
from Healthcare/Biotech-Industry-Economic...
Biocon launches diabetes, obesity management drug in UK
Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide. This follows approval from the UK's MHRA, making Biocon the first generics company to gain such approval in a major regulated market.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vB1bDCs
via...
CDSCO revamps NOC process for unapproved drug exports to boost efficiency & reduce manpower pressure
Indian drug regulator CDSCO is streamlining the process for granting No Objection Certificates (NOCs) for unapproved drug exports by moving to blanket, country-specific NOCs based on export history. This change aims to ease manpower pressure and improve regulatory efficiency, reducing annual NOCs significantly.
from Healthcare/Biotech-Industry-Economic...
New NOC process in works for export of unapproved drugs
The Indian drug regulator CDSCO is revamping the process for granting No Objection Certificates (NOCs) for the export of unapproved drugs to reduce manpower pressure and boost regulatory efficiency. Instead of buyer and quantity-specific NOCs, blanket NOCs will be issued based on export history and country approval.
from Healthcare/Biotech-Industry-Economic...
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
Healthcare experts suggest that India could increase its share in the global clinical trials market by learning from countries like China and Australia. India currently holds an 8% share, compared to China’s 29%. Experts emphasize improving regulatory speed, offering incentives, and raising patient awareness for trials. India’s clinical trials market...
AI in healthcare likely to contribute $30 bn to India's GDP by 2025: Report
Artificial Intelligence (AI) in healthcare could boost India's GDP by USD 25-30 billion by 2025, driven by initiatives like the IndiaAI Mission. Despite this, regulatory challenges, limited digital infrastructure, and workforce training gaps hinder faster AI adoption, especially compared to the banking sector.
from Healthcare/Biotech-Industry-Economic...
India's contract drug makers seek government support in China fight
India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With potential growth to $22-25 billion by 2035, the industry aims to compete globally, but currently faces delays and higher costs compared to Chinese counterparts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bH8MIAN
via...
Glenmark launches Epinephrine injection in US
Glenmark Pharmaceuticals has launched a generic version of Epinephrine injection multiple-dose vial in the US, gaining 180 days of CGT exclusivity. The injection treats hypotension from septic shock and allergic reactions. Glenmark's product, bioequivalent to BPI Labs' reference drug, adds to their institutional portfolio and achieved annual sales...
India on the verge of becoming clinical trials hub, Parexel executive says
India is poised to become a prominent site for early-stage clinical trials, particularly amid the disruptions caused by the Russia-Ukraine conflict. Parexel plans to increase its Indian workforce by over 2,000 within five years, citing lower costs and growing market potential. However, challenges such as regulatory inconsistencies and awareness regarding...
Zydus launches vaccine for new strain of influenza virus
Zydus Lifesciences introduces India's first quadrivalent influenza vaccine, VaxiFlu-4, for protection against four new virus strains as per WHO recommendations. The vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been cleared by the Central Drug Laboratory and aims to address major public health challenges by preventing flu...
No gym? No problem! 7 fun ways to stay fit at home
Skip the gym and stay fit with fun workouts like swimming, hula hooping, aerial yoga, Zumba, stair running, cycling, and exercise videos. These activities boost strength, endurance, and flexibility at home or outdoors!
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E5FOCAa
via IFT...
Indian drugmakers likely to stay competitive despite planned tariffs, Dr Reddy's says
Indian drugmakers, including Dr Reddy's, are confident about maintaining competitiveness in the generic drugs market despite potential U.S. tariffs on pharmaceutical imports. Dr Reddy's MD, GV Prasad, stated that Indian firms are awaiting more details on the tariffs but emphasized that shifting pharmaceutical production to the U.S. is impractical and...
New cases of breast cancer could be up 38 pc by 2050 globally; related deaths by 68 pc: Study
By 2050, breast cancer cases and deaths are expected to rise significantly, particularly in countries with low human development index. Researchers using the GLOBOCAN database found disparities in diagnosis and mortality rates globally. Improvements in early diagnosis and treatment, along with investing in high-quality cancer data, are essential to...
What explains feverish deal-making in India's hospital sector
India's hospital sector is experiencing a surge in deal-making, with KKR acquiring Healthcare Global for $400 million. This trend highlights the growing investor interest in the sector, driven by the increased demand for quality healthcare services. Factors such as medical tourism, government support, and expanding insurance coverage contribute to...
Amgen to invest $200 million in India site, CEO says
Amgen will invest $200 million in its new technology centre in Hyderabad, India, this year, with plans for further investments. The centre, focused on AI and data science for drug development, will employ around 2,000 people by year-end. The announcement coincides with the BioAsia conference, which will feature global pharmaceutical executives.
from...
Opiod row: Aveo Pharma says drug cleared by state authorities; govt says not approved
Aveo also claimed it is not the only company in India manufacturing a similar combination product. A recent BBC investigation report alleged that the "unlicensed addictive" combination was being illegally exported to African nations such as Ghana and Nigeria, leading to a serious public health crisis of opioid addiction.
from Healthcare/Biotech-Industry-Economic...
KKR to buy cancer care hospital chain HCG from CVC for $400 million
KKR acquires a controlling stake in Healthcare Global from CVC Capital Partners for Rs 3466 crore, strengthening its presence in the healthcare sector. The deal gives KKR up to 77% ownership, and Dr. BS Ajaikumar will take on a new role as Non-Executive Chairman.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FA3rGdI
via IFT...
FDA issues show cause notice to pharma firm in Palghar for illegal export of opioids
Palghar's Food and Drug Administration took legal action against Aveo Pharmaceuticals for alleged illegal opioid export after a BBC report revealed Tapentadol and Carisoprodol were being exported to Africa for recreational use. Authorities raided the company, seized stock, stopped production, and issued a show cause notice, following the Central government's...
India bans production of two drugs ‘behind’ opioid crisis in West Africa
The Drug Controller General of India has banned the production of tapentadol and carisoprodol after they were found to be illegally exported to African nations. These drugs, produced by Aveo Pharma, have contributed to the opioid addiction crisis in countries like Nigeria and Ghana.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uow3dQy
via...
Govt steps up inspections at pharma units to ensure quality
Government authorities have conducted risk-based inspections at over 500 pharmaceutical manufacturing units since 2022 to enhance the quality of locally produced medicines and prevent the sale of spurious drugs. Over 400 actions have been taken against units failing to meet quality standards, and inspections are expected to continue.
from Healthcare/Biotech-Industry-Economic...
Dr Agarwal's Eye Hospital appoints Sachin Tendulkar as its brand ambassador
Dr Agarwal's Eye Hospital has appointed cricket legend Sachin Tendulkar as its brand ambassador. The hospital has been conducting 100 free eye surgeries annually as a tribute to Tendulkar's 100 centuries, and Tendulkar will now help promote awareness about eye care through this collaboration.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1GLXEW
via...
Apollo Hospitals calls for liberal visa policy to boost medical tourism
Apollo Hospitals' Joint Managing Director Sangita Reddy highlights the need for a liberal visa policy to boost India's medical tourism sector, emphasizing the government's 'Heal in India' initiative. The healthcare provider plans to add around 3,000 beds and invest nearly Rs 6,000 crore for expansion over five years.
from Healthcare/Biotech-Industry-Economic...
Indian drugmakers can retain US dominance even with tariffs, says industry body
Indian pharmaceutical companies are expected to maintain their strong presence in the U.S. generic drug market despite possible high tariffs from President Donald Trump. The Pharmaceuticals Export Promotion Council of India believes these companies' competitiveness will help them navigate the new environment, although higher tariffs may squeeze the...
Pfizer board approves marketing, supply pact with Mylan for two brands
Pfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, targeting the treatment of anxiety disorders and Parkinsonism. The partnership leverages Mylan's expertise in the central nervous system therapy area to enhance product distribution and engagement with neurologists...
India, the 'pharmacy of the world' banks on bilateral talks for relief from planned US tariffs
Indian drugmakers are seeking bilateral discussions with the U.S. to avoid President Donald Trump’s proposed 25% tariff on pharmaceutical imports, according to the Indian Pharmaceutical Alliance (IPA). The U.S. is India's largest market, accounting for $8.7 billion (31%) of total pharma exports in fiscal 2024.
from Healthcare/Biotech-Industry-Economic...
India becoming an attractive option for global pharmaceutical supply chain: Macquarie Report
India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulatory support. The industry's growth could reach a high-teens CAGR due to factors like the US Biosecure Act, potentially pushing it to USD 22 billion by 2030.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J4TldtY
via...
Not scared of Trump's threats? India's drug, auto exporters see limited impact of US tariffs
Indian exporters believe that US President Trump's proposed tariffs on automobile and pharmaceutical imports will not significantly affect their competitiveness. Industry leaders suggest adjusting domestic policies to mitigate any potential impact. Indian pharmaceuticals and auto components are expected to remain resilient despite the potential for...
Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans
US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and impacting margins. Indian companies and stock markets brace for the impact, as India dominates with 30% of exports to the US. Firms may face challenges balancing costs and profit margins.
from Healthcare/Biotech-Industry-Economic...
Tata Group to invest Rs 500 crore in Breach Candy Hospital Expansion
Tata Group will invest Rs 500 crore in Breach Candy Hospital, becoming its largest financial backer. This will allow Tata Group to add three representatives to the board and support infrastructure and technology improvements. Chairman N Chandrasekaran will replace Deepak Parekh as chairman of Breach Candy Hospital Trust from October 2025, while Parekh...
Pharma market in good health; lifestyle diseases may be rising
The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the data showed. According to Pharmarack, emerging molecules like vericiguat, finerenone and midodrine also posted robust growth.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsrhiJD
via IFT...
Practo appoints Jagnoor Singh as COO
Practo has appointed Jagnoor Singh as its new COO to boost growth and refine processes. With 16 years of experience at top firms, Singh will collaborate with CEO Shashank ND to expand into new markets and enhance existing ones, aiming to make healthcare more accessible and affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PF1sY0
via...
SMT appoints Bhargav Kotadia as chief executive officer
Samara Capital-backed Sahajanand Medical Technologies has named Bhargav Kotadia as CEO and Jose Calle Gordo (‘Pepe’) as chairman, effective April 1. Kotadia replaces Ganesh Sabat, while founder Dhirajlal Kotadia becomes chairman emeritus. The new leadership aims to drive SMT’s growth in cardiovascular technologies, focusing on delivering high-quality...
Glenmark, FDC recall products in US due to manufacturing issues: USFDA
Glenmark Pharmaceuticals and FDC Ltd are recalling some products in the US market. Glenmark is recalling certain strengths of Carvedilol tablets due to impurity issues. FDC Ltd is recalling bottles of glaucoma medication Timolol Maleate due to defective containers. Both recalls were initiated in January 2025 to ensure safety.
from Healthcare/Biotech-Industry-Economic...
Aurobindo Pharma to commence supplies to Europe from China plant in April
Aurobindo Pharma will start supplying products from its new China facility to Europe by April 2024. The company is ramping up production after receiving European regulatory approvals. Plans to enter the US market are also in progress. Aurobindo expects significant revenue growth from this facility over the next two to three years.
from Healthcare/Biotech-Industry-Economic...
MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention
MSD Pharmaceuticals and Delhi Capitals have partnered to raise cervical cancer prevention awareness in India. The women's T20 team will display this message on their jerseys during matches. The initiative aims to reduce stigma, provide information accessibility, and promote preventive health measures. Cervical cancer remains a major issue in India...
'Discover and Make in India' to drive innovation in pharma, says Dilip Shanghvi, Founder & Managing Director, Sun Pharmaceutical Industries
India has established itself as a global leader in pharmaceutical production, with potential for further growth through increased investment in drug discovery. Companies like Sun Pharma are already making strides with innovative products and clinical trials, promising a future where India can contribute significantly to global healthcare.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences inks licensing pact with Zhuhai for cancer drug
Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will handle manufacturing while Zydus will commercialize the product, targeting breast cancer and other types. The partnership includes milestone payments and profit-sharing, tapping into a market of around 531,000 units annually.
from...
Glenmark launches generic ophthalmic solution in US market
Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic Solution, which had annual sales of USD 113.5 million. This launch reflects Glenmark's growing ophthalmic portfolio and commitment to quality solutions.
from...
KKR set to buy cancer chain HCG
KKR is set to acquire a 51% stake in Healthcare Global Enterprises from CVC Capital Partners. The $3,128 crore deal includes an open offer for an additional 26%. HCG's founding family will retain 10.87%, while the company's growth trajectory and expanded capabilities are expected post-acquisition.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PjabrcN
via...
India, Indonesia ink milestone pact for quality assurance in traditional medicine: Ayush Minister
The Union Minister of State (Independent Charge), Ministry of Ayush, Prataprao Jadhav, stated that the MoU exchanged between India and Indonesia in the field of traditional medicine quality assurance between Pharmacopoeia Commission for Indian Medicine & Homeopathy, Ministry of Ayush and Indonesian Food and Drug Authority.
from Healthcare/Biotech-Industry-Economic...
Pharma companies must file compliance strategy
Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufacturers, with a turnover of less than ₹250 crore, have until December 31 to comply. They need to submit their upgrade plans within three months.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3BVLIr
via...
Zydus Lifesciences in pact with Synthon for specialty oncology product in US
Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel oncology product, focusing on reducing pill burden and improving patient compliance. Synthon will handle development and manufacturing, while Zydus will oversee NDA submission and marketing in the US by 2026.
from Healthcare/Biotech-Industry-Economic...
Govt extends Schedule M implementation deadline till year-end for small, medium pharma firms
The implementation of revised Schedule M for good manufacturing practices has been conditionally extended to December 31, 2025, for small and medium pharmaceutical firms with turnover of Rs 250 crore or less. These firms must submit an upgrade plan by February 11, 2025, to qualify for the deadline extension. The updated regulations aim to enhance product...
Biovet's new vax developed to treat skin disease of livestock gets regulator's license
Biovet has secured a license from CDSCO for Biolumpivaxin, the world's only marker vaccine for Lumpy Skin Disease in cattle and buffaloes. Developed with the DIVA concept, it ensures high safety and efficacy while distinguishing between infected and vaccinated animals, a crucial step toward India's self-reliance in veterinary healthcare.
from Healthcare/Biotech-Industry-Economic...
Over 3k brands hit pharma mkt, cancer drug tops in sales
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, reflecting a rise in cancer cases. Enhertu, exempted from customs duty, has significantly contributed to AstraZeneca's sales, highlighting the growing demand for innovative cancer treatments.
from Healthcare/Biotech-Industry-Economic...
Biocon betting big on new product launches for growth
Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrates development, production, distribution, and market deployment. Biocon Biologics has acquired Viatris' global biosimilars business, boosting revenue. The company is building a strong brand presence globally, especially...
Bajaj dynasty said to earmark Rs 10,000 crore for hospital chain
Bajaj Group earmarks 100 billion rupees ($1.1 billion) to establish a chain of affordable, high-class hospitals across India. This move aligns with the nation's growing healthcare needs and increased insurance coverage. Led by Nirav Bajaj, this initiative marks the conglomerate's new venture amid its diversified portfolio, including Bajaj Auto and...
India's Pharma market to expand 2.4 times over next 5 years, share in global market to hit 5 pc: Report
India's pharmaceutical industry is set to grow significantly, with its share in the global market expected to reach 5% by 2030. Currently valued at USD 55 billion, the market is projected to hit up to USD 130 billion, driven by strong domestic demand and increasing global exports.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zHfUdq
via...
NPPA asks retailers to display drug prices on websites
The National Pharmaceutical Pricing Authority (NPPA) will take action if the pharmacies fail to comply with the diktat, it said in an order. It may be noted that the online pharmacies and other online platforms selling medicines were not displaying the prices of drugs, firmly refusing to do so citing extract from the Para 24 of the Drugs (Price Control)...
Sanofi Healthcare gets marketing authorisation for cGVHD drug
Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host disease (cGVHD), a condition that occurs after allogeneic stem cell transplants. The drug, approved by USFDA and CDSCO, offers a new treatment option for patients over 12 years old after other treatments have failed.
from Healthcare/Biotech-Industry-Economic...
Glenmark, Cosmo get MHRA nod for acne treatment medication
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion...
Rashmi Saluja's re-appointment to REL board fails to get shareholders' stamp
Rashmi Saluja's reappointment to Religare Enterprises' board was overwhelmingly rejected by shareholders, with 97.53% voting against it. Despite Saluja's refusal to step down, the resolution was blocked, and the Delhi High Court affirmed that executive directors must retire by rotation as per the Companies Act.
from Healthcare/Biotech-Industry-Economic...
India's CDMO market set to double by 2028 amid Asia's healthcare boom
India's CDMO market is set to grow from USD 7 billion to USD 14 billion by 2028. This growth is driven by its strong stance in API manufacturing and cost advantages over China. Global pharmaceutical companies are diversifying supply chains to India. The broader APAC healthcare sector is also expanding rapidly, supported by rising income levels.
from...
Pharma exports expected to double to $65 billion by 2030: Report
India's pharmaceutical exports are set to reach USD 65 billion by 2030 and USD 350 billion by 2047, placing India among the top five global exporters by diversifying its product range. The report highlights the need for innovation, quality focus, and collaboration between the government and private sector to achieve this growth, emphasizing specialty...
What are nutraceuticals and why are they gaining popularity in India
Nutraceuticals in India are gaining popularity due to rising health awareness, an increase in lifestyle diseases, and a shift toward natural products. The market is expected to grow significantly, driven by government initiatives, increased disposable incomes, and the expansion of online retail models.
from Healthcare/Biotech-Industry-Economic Times...
Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic business
Alkem Laboratories has announced two strategic acquisitions totaling Rs 287 crores to strengthen its domestic market presence. The company will acquire Adroit Biomed for Rs 140 crore and Bombay Ortho Industries for Rs 147 crore. These acquisitions will diversify Alkem's portfolio and meet growing market demands.
from Healthcare/Biotech-Industry-Economic...
IHH Healthcare seeks damages of upto Rs 10,930 cr from Daiichi Sankyo for obstructing open offer for Fortis
IHH Healthcare is seeking up to Rs 10,930 crore in damages from Daiichi Sankyo for allegedly obstructing NTK's acquisition of Fortis Healthcare. IHH announced that NTK has submitted an additional claim with an expert report to quantify the damages. The dispute stems from a 2018 open offer block by Daiichi's contempt plea against Fortis founders.
from...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will manage development and manufacturing, receiving up to $131.6 million. Dr Reddy's gains exclusive rights to market the drug in the US and Europe.
from Healthcare/Biotech-Industry-Economic Times...
GBS patient treated in Gurugram, cases rise in Pune
Healthcare authorities are closely monitoring the outbreak of Guillain-Barre Syndrome (GBS) in Pune as cases rise to 158, with five deaths suspected in Maharashtra. Doctors report instances of muscle weakness and dysfunction, primarily affecting the younger population, and are coordinating efforts with the Centre to control the spread.
from Healthcare/Biotech-Industry-Economic...
ICMR initiates process of vaccine against avian influenza
The ICMR has launched efforts to develop a human vaccine against the highly-pathogenic avian influenza H5N1. This virus poses a significant public health risk due to its high mortality rate and potential to cause global pandemic. Recent outbreaks highlight the urgency of vaccine development for better preparedness.
from Healthcare/Biotech-Industry-Economic...
Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'
Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high prices maintained by patent monopolies. Activists call for generic production by Indian manufacturers and GST exemption on locally available drugs to effectively reduce prices and provide affordable treatment.
from...
Want youthful skin? Eat these 5 anti-aging foods daily - here's why
Aging is a natural process, but the right diet can slow down its effects, keeping your skin youthful and vibrant. Here are five anti-aging foods to include in your daily routine:
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IckKz5O
via IFT...
Sun Pharma elevates Aalok Shanghvi as COO
Sun Pharma, India's largest drugmaker, has designated Aalok Shanghvi as Chief Operating Officer. Aalok, the son of promoter Dilip Shanghvi, has held various strategic roles since joining in 2006 and has been a whole-time director since June 2023. Sun Pharma reported revenue of ₹48,496 crore for FY24, with a market valuation of ₹4.17 lakh crore.
from...
World Cancer Day 2025: 6 facts you probably didn't know about cancer
Observed every year on February 4th, World Cancer Day is a global initiative to raise awareness about cancer prevention, early detection, and treatment. It unites individuals, communities, and organizations to highlight the challenges of cancer and encourage action.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xD5R3Nq
via IFT...
Making India a global hub for healthcare: Suneeta Reddy, MD, Apollo Hospitals
This year's budget focuses on improving healthcare in India, with initiatives like 200-day care chemo centres, increasing medical seats, and promoting medical tourism. The government aims to encourage discretionary spending by boosting disposable income, facilitating better access to quality healthcare, and simplifying regulations across sectors.
from...
Budget 2025 impact: Pharma and Healthcare
The Budget 2025 has indirect positive impacts on pharma and healthcare sectors with the addition of 36 lifesaving drugs attracting a 5% customs duty. The budget plans to add 75,000 medical college seats over five years and establish 200 day care cancer centres by FY26.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZW7dvIu
via IFT...
Union Budget 2025: Key healthcare moves for cancer treatment, gig workers, & medical education
Finance Minister Nirmala Sitharaman's Union Budget 2025-26 includes initiatives such as establishing Daycare Cancer Centres in all district hospitals, providing healthcare coverage for gig workers under PM-JAY, expanding medical education seats by 10,000, and ensuring broadband connectivity to all government schools and healthcare centres, particularly...
Budget 2025 for healthcare: Big changes in import duty for lifesaving medicines
Finance Minister Nirmala Sitharaman presented the Union Budget 2025, highlighting measures to enhance healthcare affordability. Key initiatives include the exemption of 36 lifesaving drugs from Basic Customs Duty, and 37 more medicines from the same duty along with the introduction of patient assistance programmes providing free treatments.
from Healthcare/Biotech-Industry-Economic...
Budget may roll out HPV jab for cervical cancer
The Union budget may announce the rollout of the human papillomavirus (HPV) vaccine for cervical cancer prevention under the national immunisation programme. This move aligns with FM Nirmala Sitharaman's focus on cervical cancer vaccination, potentially providing the vaccine, currently available only in private hospitals at high costs, to more girls.
from...
Aerial angels: How drones can save your life
The Economic Survey 2024-25 highlighted how drones can address quality, accessibility, and affordability issues in India's healthcare. Projects like ‘Medicines from the Sky’ and ‘i-DRONE’ have already demonstrated their potential in a big way, cutting delivery times drastically and improving emergency responses, showcasing their role in saving lives.
from...
Apollo Hospitals, Hackensack Meridian announce collaboration
Apollo Hospitals Group has teamed up with Hackensack Meridian Health to develop innovative healthcare solutions. They aim to enhance patient care, improve affordability, and promote community health through joint initiatives. Key focus areas include addressing workforce shortages and oncology collaboration. This partnership seeks to leverage mutual...
This New Year explore the ABCD of diabetes
Diabetes and heart health are influenced by A1C, body weight, cardiovascular health, and the duration of diabetes. Excess weight, especially around the waist, increases the risk for heart disease and makes diabetes management tougher. Losing 5-10% of body weight can significantly improve both heart and blood sugar levels. Small health changes now can...
Roche Pharma India to appoint Rajwinder Mehdwan as country general manager
Roche Pharma India has announced that Rajwinder Mehdwan will take over as the country general manager from April 1, 2025, replacing V Simpson Emmanuel. Rajji brings over 20 years of healthcare industry experience and has held various leadership roles at Roche and Johnson & Johnson.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pKPmLlZ
via...
Budget 2025: Will FM Sitharaman give India’s healthcare sector the boost it desperately needs?
Union Budget: India's healthcare sector anticipates major support from the Union Budget 2025, with expectations for increased allocations to meet National Health Policy goals. Addressing disparities between urban and rural healthcare, and offering tax exemptions and higher insurance coverage are critical to enhance healthcare access for the 'missing...
Cipla sees no major impact on biz from Donald Trump admin's decision to pause foreign aid: Umang Vohra
Cipla, a drugmaker involved in supplying HIV medications through US-supported programmes, anticipates minimal impact from the Trump administration's decision to pause foreign aid, including PEPFAR. The company's sales from PEPFAR are below $5 million, with low margins. Cipla's reduced dependence on tenders and significant US investments have de-risked...
Medicine e-tailer Sastasundar says its deal with Flipkart is now over
Flipkart has ended its partnership with Sastasundar in the online pharmacy and healthcare sector. Sastasundar has regained its brand's intellectual property rights and plans to launch its own app. This follows Flipkart’s decision to exit the health business. The transaction resulted in a one-time technical accounting loss for Sastasundar Ventures.
from...
Ophthalmic devices maker Appasamy appoints Annaswamy Vaidheesh as non-executive chairman
Appasamy Associates has appointed Annaswamy Vaidheesh as its non-executive chairman. With over 35 years of experience in the healthcare and med-tech industry, Vaidheesh brings valuable insights to the company. His strategic vision aims to drive growth, innovation, and global expansion in ophthalmic equipment and devices.
from Healthcare/Biotech-Industry-Economic...
Union Budget: Will India’s life sciences sector get the prescription for success?
Union Budget 2025: India's life sciences sector expects government reforms in the upcoming Union Budget to support growth and innovation. Key requests include incentives for R&D and domestic manufacturing, API infrastructure development, and AI investment in drug discovery. The sector also seeks increased healthcare spending and steps towards Universal...
Guillain-Barré Syndrome: What is it, what are the key symptoms, and are you at risk?
Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder affecting the nervous system, causing muscle weakness and paralysis. Learn about symptoms, treatment, prevention, and rising cases in Maharashtra.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8zl6JBf
via IFT...
Health Ministry sends team to Pune amid surge in Guillain-Barré Syndrome cases
A high-level team has been sent to Pune by the Union Ministry of Health and Family Welfare to address the surge in Guillain Barre Syndrome (GBS) cases. With over 100 cases reported and one suspected death, the team will assist the State health authorities with public health interventions and management.
from Healthcare/Biotech-Industry-Economic Times...
Policybazaar's parent firm eyes 25% stake in PB Healthcare; to invest Rs 860 cr for establishing hospitals
PB Fintech, the parent company of Policybazaar, invests Rs 860 crore for a 25% stake in PB Healthcare, aiming to establish hospitals with 1,000 beds in its first year. The venture will ensure cashless treatment without pre-authorisation, aiming to tackle rising healthcare costs. Initially, hospitals will be set up around NCR before expanding across...
China+1 opens larger share for India in global pharma manufacturing beyond generics: BCG report
India is set to capture a larger share of the global pharmaceutical market beyond generics, driven by the "China+1" strategy as companies diversify from China. Investments are pouring into India's affordable pharma services and growing infrastructure. India and Singapore are leading hubs for healthcare innovation, with Asia's healthcare market projected...
Pharma companies may get time till December to comply with schedule M norms
The government may extend the deadline for drug manufacturers to comply with revised Schedule M standards until December 2025. A final notification is expected soon, allowing MSMEs additional time to upgrade facilities.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hplYXr3
via IFT...
Budget 2025: SBI urges higher healthcare spending, uniform GST on medical devices and tax exemptions
The Union Government's Budget 2025 should focus on revitalizing the insurance and healthcare sectors. Suggestions include exempting GST and taxes on term and health insurance premiums, increasing the healthcare budget to 5% of GDP, and rationalizing GST rates on medical devices. These measures aim to enhance insurance penetration and bolster healthcare...
Drug quality, ease of doing biz to top govt-pharma companies' talks
The health ministry is set to meet pharma industry representatives to discuss improving drug quality after several instances of exports failing standards. The meeting on January 31 will also address ease of business concerns. Inspections have intensified following WHO's link between Indian cough syrups and deaths in Gambia and a report highlighting...
Union Budget 2025: Pharma, healthcare sectors seek 3 per cent hike in budget allocation
Budget: The Indian pharmaceutical and healthcare industry seeks increased government support in the Union Budget 2025, including a 2.50-3% rise in healthcare budget allocation, re-introduction of weighted average tax benefits for R&D, and reduced GST on health insurance premiums. This support aims to enhance infrastructure and affordability, thus...
Diabetes, heart, and kidneys: The hidden links you can’t afford to ignore
Diabetes impacts not just blood sugar but also the heart and kidneys. High sugar levels strain these organs, causing complications. Regular checkups, healthy lifestyle choices, and weight management are vital for minimizing risks and managing health effectively. Early detection and personalized treatments can significantly improve outcomes for people...
Strategy is to first serve India's vaccine needs and then move on to exports, says Adar Poonawalla
Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine development and aims to supply new vaccines globally after meeting India's needs. The investment in Karan Johar's Dharma Productions reflects their broader...
NMC starts probe against doctors over AbbVie-sponsored foreign trips
The National Medical Commission (NMC) initiates an investigation into doctors whose foreign trips, funded by AbbVie Healthcare, breached the Uniform Code for Pharmaceutical Practices. AbbVie spent over a crore on travel for 30 doctors to Monaco and Paris, prompting scrutiny and potential disciplinary action for professional misconduct.
from Healthcare/Biotech-Industry-Economic...
Dr Reddy's CEO 'optimistic' about Trump administration, says our positioning of India is favourable
Dr Reddy's Laboratories CEO expressed optimism about the Trump administration, projecting an edge due to ongoing U.S.-China tensions. The company's U.S. revenues increased slightly due to new launches despite facing pricing pressures. Consolidated net profit rose by 2% for the third quarter of 2024, driven by strong performance across markets.
from...
Bankruptcy Court approves listed-firm parental drugs India’s acquisition by IHL Lifescience
The Mumbai bankruptcy court has approved IHL Lifesciences' acquisition of Parental Drugs India Ltd. The resolution plan received 100% approval from the creditors. IHL Lifesciences will pay Rs 90 crore to acquire the company, which has liabilities of Rs 1,287 crore. This acquisition comes after Parental Drugs defaulted on a Rs 196 crore payment to Punjab...
Mumbai's Lilavati Hospital to invest Rs 800 crore to build 300 bed cancer centre in Bandra
Lilavati Hospital & Research Centre is set to invest Rs 800 crore in a new 300-bed state-of-the-art cancer hospital in Bandra, Mumbai. The facility will span 3,50,000 square feet, close to the existing Lilavati Hospital. Funding will be sourced through donations and bank debt, with groundbreaking planned in the coming months and operations starting...
Zydus receives USFDA Orphan Drug Designation for Usnoflast to treat ALS
Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS), a rare fatal neurodegenerative disease. Clinical trials indicate promising results, and further trials are planned. ALS affects over 30,000 people in the US annually.
from Healthcare/Biotech-Industry-Economic...
Centre to expand network of stroke units across country
Around 500 stroke units are operational in India, with plans to expand access to specialized care further. Union Health Secretary Punya Salila Srivastava highlighted the government's commitment to stroke prevention and control of non-communicable diseases, emphasizing the significant role of Ayushman Bharat in providing financial protection and health...
CCI clears merger of nine pharma entities with Sequent Scientific
The Competition Commission of India has approved the amalgamation of nine entities into Sequent Scientific Ltd (SSL), enhancing its position in the animal and human healthcare sectors. Furthermore, CCI has cleared the acquisition of AI Lenarco Midco by Majesty II Pte Ltd, including investments in Manjushree Technopack, thereby strengthening the involved...
Glenmark launches generic anticoagulant injectable emulsion
Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets. The 10 mg/mL single-dose ampules are bioequivalent to Vitamin K1 Injectable Emulsion USP. This launch diversifies Glenmark's institutional product portfolio and reinforces their commitment to offering affordable alternatives,...
Indian drugmakers likely to gain under the new US government
Industry experts are hopeful of India's trajectory as the US is facing shortages and backorders. They said with many blockbuster drugs were going off-patent between 2025 and 2029. "The Indian pharma industry will have a further growth opportunity in the form of generics."
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tgOescK
via ...
Jupiter Hospital to invest Rs 400 crore to set up new hospital in Ghodbunder-Mira Road
Jupiter Life Line Hospitals has acquired land in Thane to build a 300-bed hospital at an investment of Rs. 400 crore. The new hospital, planned over four years, aims to serve underserved regions. Jupiter, with 1061 beds, plans to expand its capacity to 2500 beds and is investing in new projects in Pune and Dombivli.
from Healthcare/Biotech-Industry-Economic...
Kamal Hinduja’s insights on combating India’s rising lung disease crisis
The rise in lung-related disorders in India is exacerbated by air pollution, tobacco use, and traditional cooking methods. Kamal Hinduja highlights the need for preventive measures, improved air quality, and reduction of tobacco use. The Hinduja Group, through P.D. Hinduja Hospital, is addressing these issues with awareness campaigns, advanced treatments,...
Biocon urges government to exempt cancer, rare-disease drugs from tax in budget
India should eliminate tax on drugs for cancer treatment and chronic diseases, urged Biocon's chairperson Kiran Mazumdar-Shaw, ahead of the budget. She highlighted the heavy financial burden on patients and called for making lifesaving therapies affordable by removing taxes and cutting import duties on medical equipment.
from Healthcare/Biotech-Industry-Economic...
Bengaluru company launches low-cost treatment for blood cancer
Immuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Hodgkin Lymphoma. This therapy is priced at a fraction of similar treatments in the West and offers a new option for aggressive blood cancers.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aN72ZvG
via...
Private hospital in Kolkata launches rooftop helipad for emergency services
Kolkata's Desun Hospital successfully conducted a trial run of its newly launched rooftop helipad with an Agusta 109 SP helicopter, enhancing emergency healthcare services. Approved by the DGCA, the helipad aims to provide critical care air ambulance services for patients across West Bengal, North-East, and Eastern India, ensuring faster medical intervention.
from...
Halt illegal imports of refurbished medical gear: Drug regulator
India's drug regulator has instructed Customs to prevent the entry of refurbished medical devices, as these lack regulation under existing rules. This move addresses concerns about patient safety and supports domestic manufacturers. Imports are halted until a policy framework is established, impacting the pre-owned medical equipment market, which aids...
Competition Commission of India penalises investment manager of Goldman Sachs AIF for failing to notify Biocon deal
The Competition Commission of India has imposed a Rs 40 lakh penalty on Goldman Sachs AIMPL for not notifying the regulator about a deal involving optionally convertible debentures issued by Biocon Biologics. CCI ruled the deal was strategic and required prior approval.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qp1iXRJ
via IF...
A Healthy Dialogue: Future of health sector cooperation under the Trump administration
India faces a complex health cooperation agenda with the incoming US administration. Key focus areas include trade in pharmaceuticals, pandemic preparedness, vaccine development, digital health, and climate resilience in health systems. Ensuring continued collaboration and addressing emerging challenges requires strategic planning and negotiation.
from...
Clear labelling of industrial & medical oxygen must, PMO tells health ministry
The Prime Minister's Office has instructed the health ministry to ensure proper labelling of oxygen cylinders to differentiate medical oxygen from industrial oxygen. This action follows concerns raised by lawmaker Ajeet Madhavrao Gopchade about the importance of quality medical oxygen to prevent infections and health complications in patients, especially...
Japanese pharma Takeda launches innovation centre, eyes to onboard AI-driven talent
Takeda opens its first Innovation Capability Centre in Bengaluru, targeting to hire 750 professionals in AI, data science, and cybersecurity. The facility aims to advance AI in drug discovery, clinical trials, and patient care. The company plans to launch its Dengue vaccine in India by 2026 and expand its focus on inflammation, oncology, and rare conditions.
from...
Alembic Pharmaceuticals gets USFDA nod for generic antidepressant tablets
Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Brexpiprazole tablets, used in treating major depressive disorder and schizophrenia. The approval covers strengths from 0.25 mg to 4 mg, and the market size for these tablets is estimated at USD 2 billion for the year ending September 2024.
from Healthcare/Biotech-Industry-Economic...
Tata Group and IISc partner to establish medical school to pioneer healthcare education and research
The Tata Group has partnered with the Indian Institute of Science (IISc) to establish the Tata IISc Medical School on the IISc Bengaluru campus with a contribution of Rs 500 crore. The school aims to integrate clinical research and medical education through innovative degree programs and global collaborations, focusing on various medical specialities.
from...
Quadria Capital buys 10% stake in pharma company Aragen Life Sciences for $100 million
Aragen Life Sciences secured a $100 million investment from Quadria Capital, selling a 10% stake at a $1.4 billion valuation. This funding supports strategic expansion to meet demand from US and European innovators. Aragen revenue for FY24 and FY25 is projected at Rs 1,675 crore and Rs 1,800 crore respectively.
from Healthcare/Biotech-Industry-Economic...
Healthcare Industry seeks tax cuts on insurance premiums & increased budgetary allocation in Budget 2025
Industry experts expect the 2025 Union Budget to include reforms for the healthcare sector. They seek increased government spending, focus on preventive healthcare, tax uniformity, and better insurance policies. Stakeholders hope for measures to improve healthcare infrastructure, especially in rural areas, and initiatives to support urban low-income...
AIG Hospitals to invest Rs 800 crore in new oncology centre
AIG Hospitals is investing Rs 800 crore in a new dedicated oncology centre in Hyderabad, featuring the cutting-edge Proton Beam Therapy system from Belgium-based IBA. This marks a significant milestone in delivering advanced cancer care in India, especially for treating complex tumours near critical organs.
from Healthcare/Biotech-Industry-Economic...
Pharma lobby seeks 2-year extension of schedule M deadline
Pharma lobby group FOPE has requested the government to extend the compliance deadline for the revised Schedule M till December 31, 2026. This is to allow manufacturers time to make necessary upgrades. The government is currently considering a draft notification suggesting an extension until December 31, 2025, for smaller manufacturers.
from Healthcare/Biotech-Industry-Economic...
Practo reports 22pc rise in revenue in FY24, GMV crosses Rs 3,500 crore
Practo, a health-tech platform, reported a 22% revenue growth to Rs 240 crore for the 2023-24 financial year, achieving a GMV of Rs 3,500 crore. The company reduced its losses to Rs 17 crore and had its first profitable quarter. Practo focuses on improving healthcare outcomes and expanding its presence in India and abroad.
from Healthcare/Biotech-Industry-Economic...
Kotak Strategic Situations Fund buys into Neuberg Diagnostics
Kotak Strategic Situations India Fund II has invested Rs 940 Crore in Neuberg Diagnostics to support its inorganic expansion and prepare for its IPO. Neuberg aims to enhance personalized medicine and integrated diagnostics, with a strong network and market leadership in India.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HFTo0Nl
via...
Navigating cardiovascular risk in people with type 2 diabetes mellitus
The prevalence of Type 2 Diabetes Mellitus (T2DM) is rising globally, increasing cardiovascular disease (CVD) risk. Effective management strategies should include comprehensive control of blood glucose, blood pressure, and lipid levels, lifestyle changes, and the use of anti-diabetic medications to reduce CV events.
from Healthcare/Biotech-Industry-Economic...
Budget 2025: Tax cuts, sops on Pharma Inc's wish list
Pharmaceutical and hospital sector executives are requesting higher public healthcare spending, R&D incentives, and tax exemptions on life-saving drugs in the upcoming Union budget. They want more oncology drugs to be tax-exempt and lower customs duties on essential medical equipment. Executives also propose incentives for AI research and standardization...
India, Dominican Republic packaged deadly synthetic opioids into pills: US report warns of risks from online pharmacies
Nearly 35,000 online pharmacies worldwide are operating illegally, risking the distribution of ineffective or dangerous drugs, says the U.S. Trade Representative's report. The report highlights concerns about counterfeits from 19 countries and names notorious markets and platforms involved in such activities, particularly across Asia and the United...
US pharma major Eli Lilly and Co plans to establish new GCC in Hyderabad
US pharma company Eli Lilly plans to open a new global capability centre in Hyderabad by mid-2025. It will recruit over 1,000-1500 skilled workers, including technology engineers and data scientists. The centre will focus on expanding capabilities in automation, artificial intelligence, software product engineering, and cloud computing to support Lilly's...
Centre may decide on rollout of Schedule M by next week
The government is set to decide on implementing the revised Schedule M for pharmaceutical products by next week. While pharma groups have requested a two-year extension, no formal feedback for this has been received. The health ministry's draft notification suggests a year's extension, with a deadline for comments until January 11.
from Healthcare/Biotech-Industry-Economic...
Chemists’ apex body against RailTel’s plan to get bids from e-pharma
In a letter to the Union minister for Railways, AIOCD President JS Shinde said that e-pharmacies are operating illegally in the country. "The High Court has prohibited operations of online pharmacies. The Central Drugs Standard Control Organization (CDSCO) in its affidavit has admitted that there is no provision for online pharmacies in India at present...
HMPV: Drug supplies from China not likely to be affected by virus
Mehul Shah, pharma expert said the operations in China have not been affected and the situation is under control. "As we all know that this virus does not cause severity, trade is unlikely to get impacted," said another expert. India is dependent on China for all major essential medicines like paracetamol, anti acid (ranitidine), cardiovascular drugs...
Botanic Healthcare raises Rs 250 crore from Stakeboat Capital & other investors
Botanic Healthcare, a nutraceutical maker based in Hyderabad, has successfully raised Rs. 250 crores in its latest equity funding round led by Stakeboat Capital, with participation from Abakkus Four2Eight Opportunities Fund and DS Group. The funds will support the company's aggressive expansion plans and growth targets in the global nutraceutical market.
from...
Alkem Laboratories to sell Pithampur unit for Rs 149 crore
Alkem Laboratories Ltd agrees to sell its manufacturing facility in Pithampur, Madhya Pradesh, to Rubicon Research Ltd for Rs 149 crore via a slump sale. The transaction supports Alkem's strategy of optimizing manufacturing facilities. Rubicon will take over the development, manufacture, distribution, and sale of pharmaceutical formulations.
from...
Zydus Lifesciences joins hands with CVS Caremark for diabetes drugs template formulary
Zydus Lifesciences Ltd enters an agreement with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR tablets for diabetes treatment to CVS’s template formulary starting January 1, 2025. This collaboration validates Zydus' new drug applications portfolio and aims to improve access to high-quality medications for patients.
from Healthcare/Biotech-Industry-Economic...
Biosimilar brand buy to help Intas Pharma take on biggies
In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NPaOJ0H
via...
Cipla rolls out mobile application for asthma screening
Cipla has launched a mobile app, CipAir, to facilitate early screening for asthma in India. The app addresses the significant asthma burden in the country, aiding in better diagnosis and treatment. Initially available on Android, it will soon be rolled out on iOS devices as well.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4adTfgC
via...
Govt grants pharma industry 12-month extension for implementing revised Schedule M
The government has extended the deadline for pharma companies to implement updated quality standards by 12 months. This extension helps smaller manufacturers upgrade facilities and meet revised Schedule M requirements. The industry initially sought a two-year extension to address challenges. Firms must now comply with improved manufacturing practices...
Study estimates about a quarter of Indian population can access stroke facility in an hour
A study finds that only a quarter of India's population can access a stroke rehabilitation centre within an hour. The research highlights the lack of facilities, with less than one ischaemic stroke centre per million people. Improvements in infrastructure are urgently needed to enhance treatment outcomes.
from Healthcare/Biotech-Industry-Economic...
5,000 drug manufacturing units may miss Schedule M deadline, industry seeks extension
Nearly half of India's 10,000 drug manufacturing units might not meet the 2025 deadline for upgrading to revised Schedule M standards, risking closure. Currently, only 2,000 comply with good manufacturing practices. The industry seeks a two-year extension for improvements, but the government hasn't announced one yet. Audits and inspections may begin...
India's first Robotic-assisted Paediatric Gait Trainer for physical rehabilitation launched
Genrobotics launched India's first robotic-assisted Paediatric Gait Trainer, G-Gaiter Paediatric. It aims to improve physical rehabilitation for children with mobility issues. The device uses advanced VR technology and interactive games for therapy. Health Minister Veena George announced its installation at SAT Hospital in Thiruvananthapuram, enhancing...
“Nothing to be alarmed”: Health Ministry eases fears as China battles surge in respiratory virus
China is seeing a surge in infections caused by human metapneumovirus (HMPV), mostly in children under 14. Despite the uptick, the Indian health ministry states there is no cause for alarm, with no substantial increase in respiratory outbreaks within the country and prepared healthcare systems.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ocJjpu
via...
DJ Group of Institutions attains net debt-free status
DJ Group of Institutions, despite the challenges following the founder's death and regulatory changes, has achieved financial stability under Rhitik Jassar's leadership, turning from a ₹215 crore debt to net debt-free status. Their financial discipline, operational excellence, and strategic financial management have garnered recognition and continued...
Big public health upgrade in works; govt hospitals could soon get more firepower
The National Essential Diagnostics List will work as a guide for health facilities in India. It suggests basic tests for village-level centres and more advanced tests for Ayushman Arogya Mandirs and primary health centres. These guidelines aim to improve timely diagnosis and treatment, especially in rural areas.
from Healthcare/Biotech-Industry-Economic...